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Endometriosis is a chronic pain condition affecting∼176millionwomen
worldwide. It is defined by the presence of endometrium-like tissue
(lesions) outside the uterus, most commonly on the pelvic peritoneum.
There is no cure for endometriosis. All endometriosis drug approvals to
date have been contraceptive, limiting their use in women of child-
bearing age. We have shown that human peritoneal mesothelial cells
(HPMCs) recovered from the pelvic peritoneum of women with endo-
metriosis exhibit significantly higher glycolysis, lower mitochondrial
respiration, decreased enzymatic activity of pyruvate dehydrogenase
(PDH), and increased production of lactate compared to HPMCs from
women without disease. Transforming growth factor-β1 (TGF-β1) is
elevated in the peritoneal fluid from women with endometriosis, and
exposure of HPMCs to TGF-β1 exacerbates this abnormal phenotype.
Treatment of endometriosis HPMCs with the pyruvate dehydrogenase
kinase (PDK) inhibitor/PDH activator dichloroacetate (DCA) normalizes
HPMC metabolism, reduces lactate secretion, and abrogates endome-
trial stromal cell proliferation in a coculture model. Oral DCA reduced
peritoneal fluid lactate concentrations and endometriosis lesion size in
a mouse model. These findings provide the rationale for targeting
metabolic processes as a noncontraceptive treatment for women with
endometriosis either as a primary nonhormonal treatment or to pre-
vent recurrence after surgery.
endometriosis | repurposing | dichloroacetate | glycolysis
Endometriosis is a chronic pain condition affecting ∼176 mil-lion women worldwide with a high socioeconomic impact. It
is defined by the presence of endometrium-like tissue (lesions)
outside the uterus, most commonly on the pelvic peritoneum.
There is no cure for endometriosis, and it is difficult to treat.
Recurrence rates after surgery to remove lesions are as high as
50% after 5 y (1). Current medical treatments are contraceptive,
often with unpleasant side effects.
Endometriosis exhibits cancer-like features. For example, tumor
cells are programmed by TGF-β1 to use aerobic glycolysis, resulting
in increased secretion of lactate (2). TGF-β1 and lactate are both
elevated in the peritoneal fluid (PF) of women with endometriosis,
and this is paralleled by a switch from normal mitochondrial
respiration toward glycolysis in the human peritoneal mesothelial
cells (HPMCs) that line the pelvic cavity (3). In tumors, lactate is
considered a key factor in driving cell invasion, angiogenesis, and
immune suppression (2), changes that are also implicated in the
establishment and survival of endometriosis lesions.
In this study, we have demonstrated that we can reverse the
aberrantly increased glycolysis of HPMCs with dichloroacetate
(DCA) and that oral administration of DCA reduces the size of
lesions in a mouse model.
Results
Peritoneal Mesothelial Cells from Women with Endometriosis Have a
Glycolytic Phenotype. We documented higher levels of basal
glycolysis (P = 0.0499), lower mitochondrial respiration
(ATP-linked) (P = 0.0400), and higher lactate secretion (P =
0.0004) in HPMCs from women with endometriosis compared to
women without disease (Fig. 1 A–C). “Endo” HPMCs exhibited
decreased enzymatic activity of pyruvate dehydrogenase (P =
0.0025) (Fig. 1D).
DCA Corrected the Glycolytic Phenotype of Peritoneal Mesothelial
Cells from Women with Endometriosis and Decreased Stromal Cell
Proliferation In Vitro. Treatment of Endo HPMCs with DCA
normalized their metabolic phenotype and increased PDH
activity, in the presence or absence of TGF-β1 (Fig. 1 E–H). In a
coculture system (Fig. 1I), treatment of endometriosis HPMCs
with DCA decreased basal and TGF-β1–stimulated HPMC
lactate secretion (P = 0.0003) and proliferation of endometrial
stromal cells (P = 0.0002, Fig. 1 J and K).
DCA Reduces Lactate Concentrations and Endometriosis Lesion Size in
a Mouse Model. In a preclinical mouse model of endometriosis
(4), treatment with oral 100 mg/kg DCA for 7 d reduced PF
lactate concentrations (P = 0.0360) and the size of endometriosis
lesions (P = 0.02) (Fig. 1 L–N).
Discussion
HPMCs from women with endometriosis synthesize and secrete
more lactate than cells recovered from women without lesions.
Lactate can stimulate cell migration and invasion, and immune
escape during tumorigenesis, with the same processes implicated
in the etiology of endometriosis (2). We postulate that increased
lactate concentrations in pelvic PF may create an environment
that promotes invasion of ectopic endometrial cells into the
peritoneum so that they form lesions.
We have shown that Endo HPMCs exhibit a greater dependence
on energy production through glycolysis under aerobic conditions
than those of women who are disease-free. This abnormal cellular
energy state is corrected by treatment with the small-molecule drug
DCA. Notably, DCA reduced HPMC lactate release in vitro, and
oral dosing of mice reduced endometriosis lesion size in vivo. DCA
is a pyruvate dehydrogenase kinase (PDK) inhibitor used to
treat cancer (5). Four different isoforms of PDK (PDK1–4)
exist with variable expression reported: PDK1 appears to have
the highest sensitivity to inhibition by DCA (6). PDK inhibition
reduces phosphorylation of PDH, increasing PDH activity leading
to lower release of metabolites such as lactate. DCA also inhibits
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proproliferative and proangiogenic transcription factors such as
HIF-1α (5). In a clinical trial in patients with glioblastoma, DCA
decreased tumor growth and angiogenesis (7).
While we have focused on HPMCs, an overlooked source of
metabolic factors in PF, DCA could also have an impact on other
cell types altered in endometriosis patients. Macrophages that
are present in PF or lesions of women with endometriosis exhibit
a range of phenotypes (8), and treatment with DCA could drive
metabolic reprogramming of macrophages toward a prorepair
phenotype that could have a positive impact on the pathogenesis
of the disease (9). Stromal cells in patient endometrium and
lesions exhibit up-regulation of PDK1. If apoptosis of these cells
is enhanced by DCA (10), this could contribute to reduced
lesion growth.
To translate these results to women, we are using DCA in
an exploratory-phase clinical trial (ClinicalTrials.gov identifier
NCT04046081). If effectiveness and acceptability are demon-
strated, DCA would be a nonhormonal treatment for women
with this debilitating condition.
Methods
Human Cell Culture. Approval was obtained from the Lothian Research Ethics
Committee (LREC 11/AL/0376). Samples were collected from women at-
tending a pain clinic who had a diagnosis of peritoneal endometriosis (Endo
group) or women without macroscopic evidence of endometriosis at lapa-
roscopy (“No Endo” group), all of whom had given informed consent.
Women were not on hormones and had regular menstrual cycles. HPMCs
were cultured in HOSE I media (40% Media 199, 40% IMDM, 15% heat-
inactivated FBS, 0.5% penicillin/streptomycin, and 1% L-glutamine). All
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Fig. 1. HPMCs from women with peritoneal endometriosis (Endo) had higher basal glycolytic extracellular acidification rates (ECARs) (P = 0.0499; n = 8) (A) and
lower ATP-linked respiratory oxygen consumption rates (OCRs) (P = 0.0400; n = 8) (B) than women without endometriosis (No Endo). Consistent with Endo HPMCs
having an altered metabolic phenotype, lactate secretion was higher (P = 0.0004; n = 8) (C) and enzymatic activity of pyruvate dehydrogenase (PDH) was lower
(P = 0. 0.0025; n = 6) (D) than in cells from the No-Endo women. Treatment of Endo HPMCs with DCA reduced ECAR (P = 0.0071; n = 8) (E), increased OCR (P =
0.0140; n = 8) (F), suppressed lactate secretion (P = 0.0104; n = 8) (G), and increased PDH enzymatic activity (P = 0.0373; n = 6) (H) in both the presence and absence
of TGF-β1. Lesion-in-a-dish coculture system. (I) There is no direct contact between HPMCs and stromal cells. Treatment of Endo HPMCs with DCA reduced both
basal and TGF-β1–induced lactate secretion (P = 0.0003 and P = 0.0001, respectively; n = 3). (J) Treatment of Endo HPMCs with TGF-β1 stimulated proliferation of
stromal cells (P = 0.0044; n = 3), but this did not occur if HPMCs were incubated with TGF-β1+DCA (P = 0.0002; n = 3). (K) In a mouse model, oral DCA reduced PF
lactate concentrations (P = 0.0360) (L) and reduced the size of endometriosis lesions (P = 0.02). (M) Images of endometriosis lesions frommice treated with vehicle
or oral 100 mg/kg DCA daily for 7 d (n = 10/group). (N) *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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cell/tissue samples were deidentified (anonymized but linked) prior to use in
the study. Immortalized human endometrial stromal cells [SHT290 (11)] were
grown in RPMI 1640 media plus 10% heat-inactivated FBS, 1% penicillin/
streptomycin, 1% L-glutamine, and 1% nonessential amino acids. Cells were
incubated at 37 °C under 5% CO2 in air.
Seahorse Analysis. Extracellular acidification rate (ECAR) and oxygen con-
sumption rate (OCR) were determined using a glycolytic stress test kit
(102340-100; Agilent) on a Seahorse XFe24 Analyzer. HPMCs were seeded in
microplates at a density of 2 × 104 cells per well in 500 μL of HOSE I and
incubated for 48 h. Cells were rinsed 3 times with 500 μL of prewarmed
Seahorse Assay DMEM (no glucose or pyruvate); 525 μL of same medium was
added to wells that were incubated at 37 °C for 30 min. ECAR and OCR
measurements were taken simultaneously using an 8-min protocol (3-min
mixing, 2-min wait, 3-min measure): 12 measurements were taken from each
well; 3 times baseline prior to injection of glucose (10 mM), 3 following
glucose and prior to injection of oligomycin (1 μM), 3 following oligomycin
and prior to injection of 2-deoxy glucose (100 mM), and 3 following injection
of 2-deoxyglucose. Basal glycolysis was calculated by subtracting the average
ECARs before, and after, the injection of glucose. ATP-linked mitochondrial
respiration was calculated by subtracting the average OCRs before and after
the injection of oligomycin. After assay, cells were washed with PBS and
protein was quantified to for normalization. Additional experiments used
Endo HPMCs cultured for 16 h in HOSE 1, then switched to serum-free HOSE
1 containing vehicle (water), TGF-β1 (2 ng/mL, 240-B-010; R&D Systems), DCA
(15 mM, 347795; Sigma), or TGF-β1+DCA, and incubated for 48 h before
analysis of ECAR and OCR.
Lactate and PDH Activity. Lactate concentrations were determined using an
enzymatic colorimetric kit (Alpha Laboratories) on a Cobas Fara centrifugal
analyzer (Roche Diagnostics). PDH enzyme activity was measured using a
Dipstick assay kit (ab109882; Abcam): band intensitywas analyzed using ImageJ.
“Lesion in a Dish” Coculture System. Endo HPMCs were plated in 24-well plates
at 1 × 105 cells per well (lower chamber); SHT290 were plated on Millicell-cell
culture inserts (2 × 104 per insert; pore size, 0.4 μm; Millipore) (upper
chamber) in serum-free HOSE I and RPMI 1640, respectively. After 16 h,
HPMCs were incubated with vehicle (water), DCA (15 mM), TGF-β1 (2 ng/mL),
or DCA+TGF-β1 for 48 h. Lactate concentrations were measured, and
proliferation of SHT290 cells was determined using CellTiter96 Aqueous-one
solution reagent (G3580; Promega).
Mouse Model of Endometriosis. Animal procedures were performed in ac-
cordance with UK Home Office regulations (license 70/8945). A preclinical
model of endometriosis was as in ref. 4 with the minor modification that
recipient mice were not ovariectomized or treated with E2. After 2 wk, mice
were randomly assigned to receive vehicle (water) or DCA (100 mg/kg) daily
via oral gavage for 7 d (n = 10/group). PF was recovered by lavage (2 mL of
ice-cold PBS); endometriosis lesions were fixed in 4% neutral-buffered for-
malin, lactate was measured in PF, sections of lesions were stained with H&E,
and the area was measured using ImageJ software.
Statistical Analysis. Results are expressed as mean ± SEM of a minimum of 3
independent experiments. Statistics were generated using GraphPad PRISM,
version 6. Data were analyzed using one-way ANOVA Mann–Whitney U test,
1-way ANOVA Kruskal–Wallis test, and Dunn’s multiple-comparisons test, as
appropriate.
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